Cardiovascular MorbidityPREVENT-CARDNCT06503341
A Hospital-Based Registry of Preventive Cardiology Clinics
An observational study of Cardiovascular Morbidity and Cardiovascular Risk Assesment, run by National Institute of Cardiovascular Diseases, Pakistan at 1 site in Pakistan.
Trial summary
More research is needed to articulate the most effective ways to use these tools as screening tests in cardiovascular risk assessments and how they ultimately affect CVD mortality and morbidity outcomes. Read more about this study
- Who is it for?
- Ages 18 to 90 yearsHealthy volunteers can take part
- Conditions the study is for
- Cardiovascular Morbidity, Cardiovascular Risk Assesment, Primary Prevention CVD
- What is being tested?
- Cardiovascular risk assesment
- How many people
- 10,000 participants
- Where
- 1 sitePakistan
- Study dates
- 17 Jun 2021to 1 Jun 2041
- How long will I take part?
- 10 Years
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Both genders, age 18 and above, visiting preventive cardiology clinics with or without established CVD and may or may not have CVD risk factors.
Who may be able to join
- All individuals attending the preventive cardiology clinics.
Who cannot join
- • Individuals who refused to give consent.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Pakistan1 site, 1 recruiting
- Recruiting
National Institute of Cardiovascular Diseases
Karachi, Sindh, 75510
Dr Rubina Rauf, +923002947117, drrubinarauf@gmail.com
About this study
Official title: Assessment and Control of Modifiable Risk Factors for Primary and Secondary Prevention
More research is needed to articulate the most effective ways to use these tools as screening tests in cardiovascular risk assessments and how they ultimately affect CVD mortality and morbidity outcomes. Clinicians are encouraged to continue sharing decision-making with patients to combine their unique cardiovascular risk factors and develop a comprehensive, effective treatment plan.
Read the detailed description
Study Design: observational study Duration of Study: ongoing. Sample Size: All patients presenting to preventive cardiology clinics at the National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan..
Sampling Technique: Non-probability consecutive sampling Data Collection Procedure: Verbal informed consent will be obtained from all the patients regarding their participation in the study and publication of study findings while maintaining confidentiality. Consecutive patients presenting preventive cardiology clinics at the National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan, will be included in this registry. Demographic characteristics, physical examination, clinical history, risk modification, lab assessment, and ASCVD risk score at presentation and at every follow-up will be recorded using a structural questionnaire.
Data Analysis Procedure: The Tentative analysis plan uses collected data for research publications. The statistical package for social sciences (SPSS 21) will be used to analyze baseline characteristics. The Shapiro-Wilk test will be applied to check the hypothesis of normality for quantitative (continuous) variables. Descriptive statistics such as mean ± SD, median (IQR), skewness, maximum, and minimum will be calculated for quantitative (continuous) variables. Frequency and percentages will be calculated for categorical variables.
- Being tested
- Cardiovascular risk assesment
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cardiovascular risk assesmentOther
ASCVD Score and WHO Cardiovascular Risk score.
| Study group | Role | What they receive |
|---|---|---|
| Adult patients | Adult patients with or without cardiovascular diseases. Receives: Other: Cardiovascular risk assesment |
What is being measured
The primary outcome is the main question the study is designed to answer.
cardiovascular risk assesesment
risk stratification of Cardiovascular diseases (CVD) in patients without established CVD but with CVD co morbids.we are using Atherosclerotic Cardiovascular Diseases (ASCVD) Risk Score and World Heart Organization(WHO) Risk Score for CVD Risk Assesment. In ASCVD Risk Score, we categorize population into low risk ( score <5), borderline(score between 5 and 7.4) ,intermediate( score between 7.5 an 19.9) and high risk (score>20), using all parameters for risk assesment. For WHO risk score calculation we are using WHO Risk score system for South Asia. https://cdn.who.int/media/docs/default-source/cardiovascular-diseases/south-asia.pdf?sfvrsn=c5b0d9a3_2
Measured: Ten years
Secondary outcomes (2)
Cardiovascular risk reduction
CVD risk reduction in patients with or without established CVD but with CVD co morbids.
Measured: Ten years
Cardiovascular related deaths
Estimation of patients who expired in their follow up despite CVD risk factors management.
Measured: Ten years.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jul 2024
- Study start17 Jun 2021
- Primary completion1 Jun 2031 (estimated)
- Study completion1 Jun 2041 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Cardiovascular MorbidityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 10,000 participants (estimated)
- Target duration
- 10 Years
Sponsor and investigators
- Lead sponsor
- National Institute of Cardiovascular Diseases, Pakistan
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dr Rubina Rauf, National Institute of Cardiovascular Diseases, Pakistan
- Investigators
- Dr Rubina Rauf, Principal investigator, National Institute of Cardiovascular Diseases
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06503341
- Sponsor's protocol ID
- IRB-20/2023
- Acronym
- PREVENT-CARD
- Status last verified
- Apr 2026
- First submitted
- 9 Jul 2024
- Last updated
- 13 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Rauf R, Khan MN, Sial JA, Qamar N, Saghir T, Kazmi KA. Primary prevention of cardiovascular diseases among women in a South Asian population: a descriptive study of modifiable risk factors. BMJ Open. 2024 Nov 14;14(11):e089149. doi: 10.1136/bmjopen-2024-089149.
PubMed 39542488